Frontlight ResearchEarly access
CompletedPhase 3
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
Key facts
- Who runs it
- Nationwide Children's Hospital
- Where
- Ann Arbor, Aurora, Charleston, Cleveland, Columbus, Detroit, Durham, Hershey, Houston, Kansas City, Little Rock, Los Angeles, Milwaukee, Minneapolis, Oakland, Orange, Philadelphia, Pittsburgh, Richmond, Sacramento, Salt Lake City, San Antonio, San Francisco, and Washington D.C., United StatesSee the 25 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 141 people enrolled
- Started
- 14 Jun 2022
- Ended
- 10 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- GM-CSF
- Placebo
- Record updated
- 9 April 2026
Who can take part
- Age
- 1 day to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- ≥ 40 weeks corrected gestational age to < 18 years; AND
- Admission to the PICU or CICU; AND
- Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND
- Documented or suspected infection as the MODS inciting event
Who cannot take part
- Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR
- Receipt of anakinra or GM-CSF within the previous 28 days; OR
- Previous enrollment in the GRACE-2 study
- Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR
- History of myeloid leukemia, myelodysplasia, or autoimmune thrombocytopenia; OR
- Known allergy to GM-CSF; OR
- Peripheral white blood cell count < 1,000 cells/mm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR
- Weight <3kg; OR
- Limitation of care order at the time of screening; OR
- Patients at high likelihood of progression to brain death in opinion of the clinical team; OR
- Known pregnancy; OR
- Lactating females; OR
- Resolution of MODS by MODS Day 2; OR
Where in United States
- CS Mott Children's HospitalAnn Arbor, United States
- Children's Hospital ColoradoAurora, United States
- Medical University of South CarolinaCharleston, United States
- Rainbow Babies and Children's HospitalCleveland, United States
- Nationwide Children's HospitalColumbus, United States
- Children's Hospital of MichiganDetroit, United States
- Duke UniversityDurham, United States
- Pennsylvania State UniversityHershey, United States
- Texas Children's HospitalHouston, United States
- Mercy Children's HospitalKansas City, United States
- Arkansas Children's HospitalLittle Rock, United States
- Children's Hospital of Los AngelesLos Angeles, United States
- Medical College of WisconsinMilwaukee, United States
- Children's Hospital of MinnesotaMinneapolis, United States
- University of MinnesotaMinneapolis, United States
- Benioff Children's Hospital - OaklandOakland, United States
- Children's Hospital of Orange CountyOrange, United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
- Children's Hospital of PittsburghPittsburgh, United States
- Virginia Commonwealth UniversityRichmond, United States
- University of California - DavisSacramento, United States
- Primary Children's HospitalSalt Lake City, United States
- Children's Hospital of San AntonioSan Antonio, United States
- Benioff Children's Hospital - Mission BaySan Francisco, United States
- Children's National Medical CenterWashington D.C., United States
About the trial
What the trial wants to find out
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
The 2 groups in the trial
- GM-CSFExisting treatment, for comparison
Intravenous GM-CSF 125 mcg/m2/day x 7 days
- PlaceboPlacebo, for comparison
Intravenous placebo x 7 days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- The Design of Nested Adaptive Clinical Trials of Multiple Organ Dysfunction Syndrome Children in a Single Study.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2023
- Record updated
- 9 April 2026